Use of echocardiography to evaluate the cardiac effects of therapies used in cancer treatment: What do we know?

Journal of the American Society of Echocardiography

Volumn 25, Issue 11, 2012, Pages 1141-1152

  Oreto, Lilia ^a   Todaro, Maria Chiara ^a   Umland, Matt M ^b   Kramer, Christopher ^b   Qamar, Rubina ^c   Carerj, Scipione ^a   Khandheria, Bijoy K ^b   Paterick, Timothy E ^b  

^a UNIVERSITY OF MESSINA   (Italy)

^b UNIVERSITY OF WISCONSIN MILWAUKEE   (United States)

^c Advanced Healthcare   (United States)

Author keywords

Cardiotoxicity; Chemotherapy; Diastolic and systolic function; Echocardiography; Longitudinal strain

Indexed keywords

ANTHRACYCLINE; ANTHRACYCLINE DERIVATIVE; BEVACIZUMAB; BLEOMYCIN; CAPECITABINE; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DAUNORUBICIN; DOCETAXEL; DOXORUBICIN; DOXORUBICIN DERIVATIVE; EPIRUBICIN; FLUOROURACIL; IDARUBICIN; IFOSFAMIDE; LAPATINIB; METHOTREXATE; MITOMYCIN; MITOXANTRONE; PACLITAXEL; PLACEBO; RAZOXANE; SUNITINIB; TAMOXIFEN; TAXANE DERIVATIVE; TELMISARTAN; TRASTUZUMAB; UNINDEXED DRUG; VINCA ALKALOID;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; BRADYCARDIA; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CARDIOMYOPATHY; CARDIOTOXICITY; CARDIOVASCULAR MAGNETIC RESONANCE; CELL DEATH; DIFFUSION TENSOR IMAGING; DISEASE COURSE; DRUG EFFECT; ECHOCARDIOGRAPHY; HEART; HEART EJECTION FRACTION; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE CELL; HEART RIGHT VENTRICLE EJECTION FRACTION; HEART SOUND; HEART TAMPONADE; HUMAN; HYPOTENSION; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; LOW DRUG DOSE; MULTIPLE CYCLE TREATMENT; MYOCARDITIS; OXIDATIVE STRESS; PERICARDITIS; PREDICTIVE VALUE; PROGNOSIS; SCINTIANGIOGRAPHY; SENSITIVITY AND SPECIFICITY; SIDE EFFECT; STRESS ECHOCARDIOGRAPHY; THREE DIMENSIONAL ECHOCARDIOGRAPHY; TISSUE DOPPLER IMAGING;

EID: 84867880379     PISSN: 08947317     EISSN: 10976795     Source Type: Journal    
DOI: 10.1016/j.echo.2012.09.001     Document Type: Review

References (75)

1. World Health Organization. Home page. Available at: http://www.who.int/ en/. Accessed January 26, 2012.
2. E.T. Yeh, and C.L. Bickford Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management J Am Coll Cardiol 53 2009 2231 2247
3. M. Lopez Oncologia medica pratica 2010 Società Editrice Universo Rome, Italy
4. P.P. Sengupta, D.W. Northfelt, F. Gentile, J.L. Zamorano, and B.K. Khandheria Trastuzumab-induced cardiotoxicity: heart failure at the crossroads Mayo Clin Proc 83 2008 197 203
5. D. Cardinale, A. Colombo, G. Lamantia, N. Colombo, M. Civelli, and G. De Giacomi Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy J Am Coll Cardiol 55 2010 213 220
6. W. Darko, A.L. Smith, E.L. King, and S.J. Grethlein Mitoxantrone-induced cardiotoxicity J Oncol Pharm Pract 7 2001 47 48
7. M.I. Gharib, and A.K. Burnett Chemotherapy-induced cardiotoxicity: current practice and prospects of prophylaxis Eur J Heart Fail 4 2002 235 242
8. L. Gianni, E. Salvatorelli, and G. Minotti Anthracycline cardiotoxicity in breast cancer patients: synergism with trastuzumab and taxanes Cardiovasc Toxicol 7 2007 67 71
9. D. Cardinale, A. Colombo, R. Torrisi, M.T. Sandri, M. Civelli, and M. Salvatici Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation J Clin Oncol 28 2010 3910 3916
10. M.S. Ewer, and S.M. Lippman Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity J Clin Oncol 23 2005 2900 2902
11. E.A. Perez, M. Koehler, J. Byrne, A.J. Preston, E. Rappold, and M.S. Ewer Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials Mayo Clin Proc 83 2008 679 686
12. T.F. Chu, M.A. Rupnick, R. Kerkela, S.M. Dallabrida, D. Zurakowski, and L. Nguyen Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib Lancet 370 2007 2011 2019
13. M.L. Telli, R.M. Witteles, G.A. Fisher, and S. Srinivas Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate Ann Oncol 19 2008 1613 1618
14. A. Necchi, N. Nicolai, M. Colecchia, M. Catanzaro, T. Torelli, and L. Piva Proof of activity of anti-epidermal growth factor receptor-targeted therapy for relapsed squamous cell carcinoma of the penis J Clin Oncol 29 2011 e650 e652
15. D.D. Von Hoff, M.W. Layard, P. Basa, H.L. Davis Jr., A.L. Von Hoff, and M. Rozencweig Risk factors for doxorubicin-induced congestive heart failure Ann Intern Med 91 1979 710 717
16. S.M. Swain, F.S. Whaley, and M.S. Ewer Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials Cancer 97 2003 2869 2879
17. N. Fallah-Rad, J.R. Walker, A. Wassef, M. Lytwyn, S. Bohonis, and T. Fang The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II-positive breast cancer treated with adjuvant trastuzumab therapy J Am Coll Cardiol 57 2011 2263 2270
18. R.G. Schwartz, W.B. McKenzie, J. Alexander, P. Sager, A. D'Souza, and A. Manatunga Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography Am J Med 82 1987 1109 1118
19. M.L. Chuang, M.G. Hibberd, C.J. Salton, R.A. Beaudin, M.F. Riley, and R.A. Parker Importance of imaging method over imaging modality in noninvasive determination of left ventricular volumes and ejection fraction: assessment by two- and three-dimensional echocardiography and magnetic resonance imaging J Am Coll Cardiol 35 2000 477 484
20. R. Hoffmann, S. von Bardeleben, F. ten Cate, A.C. Borges, J. Kasprzak, and C. Firschke Assessment of systolic left ventricular function: a multi-centre comparison of cineventriculography, cardiac magnetic resonance imaging, unenhanced and contrast-enhanced echocardiography Eur Heart J 26 2005 607 616
21. S. Malm, S. Frigstad, E. Sagberg, H. Larsson, and T. Skjaerpe Accurate and reproducible measurement of left ventricular volume and ejection fraction by contrast echocardiography: a comparison with magnetic resonance imaging J Am Coll Cardiol 44 2004 1030 1035
22. L. Sugeng, V. Mor-Avi, L. Weinert, J. Niel, C. Ebner, and R. Steringer-Mascherbauer Quantitative assessment of left ventricular size and function: side-by-side comparison of real-time three-dimensional echocardiography and computed tomography with magnetic resonance reference Circulation 114 2006 654 661
23. B.V. Jensen, T. Skovsgaard, and S.L. Nielsen Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients Ann Oncol 13 2002 699 709
24. J. Ganame, P. Claus, A. Uyttebroeck, M. Renard, J. D'hooge, and B. Bijnens Myocardial dysfunction late after low-dose anthracycline treatment in asymptomatic pediatric patients J Am Soc Echocardiogr 20 2007 1351 1358
25. F. Dodos, T. Halbsguth, E. Erdmann, and U.C. Hoppe Usefulness of myocardial performance index and biochemical markers for early detection of anthracycline-induced cardiotoxicity in adults Clin Res Cardiol 97 2008 318 326
26. G.E. Stapleton, S.L. Stapleton, A. Martinez, N.A. Ayres, J.P. Kovalchin, and L.I. Bezold Evaluation of longitudinal ventricular function with tissue Doppler echocardiography in children treated with anthracyclines J Am Soc Echocardiogr 20 2007 492 497
27. A.L. Jones, M. Barlow, P.J. Barrett-Lee, P.A. Canney, I.M. Gilmour, and S.D. Robb Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring Br J Cancer 100 2009 684 692
28. A. Seidman, C. Hudis, M.K. Pierri, S. Shak, V. Paton, and M. Ashby Cardiac dysfunction in the trastuzumab clinical trials experience J Clin Oncol 20 2002 1215 1221
29. T.M. Suter, M. Procter, D.J. van Veldhuisen, M. Muscholl, J. Bergh, and C. Carlomagno Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial J Clin Oncol 25 2007 3859 3865
30. V.B. Pai, and M.C. Nahata Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention Drug Saf 22 2000 263 302
31. L.J. Ayash, J.E. Wright, O. Tretyakov, R. Gonin, A. Elias, and C. Wheeler Cyclophosphamide pharmacokinetics: correlation with cardiac toxicity and tumor response J Clin Oncol 10 1992 995 1000
32. L.J. Steinherz, T. Graham, R. Hurwitz, H.M. Sondheimer, R.G. Schwartz, and E.M. Shaffer Guidelines for cardiac monitoring of children during and after anthracycline therapy: report of the Cardiology Committee of the Childrens Cancer Study Group Pediatrics 89 1992 942 949
33. S.E. Lipshultz, S.P. Sanders, A.M. Goorin, J.P. Krischer, S.E. Sallan, and S.D. Colan Monitoring for anthracycline cardiotoxicity Pediatrics 93 1994 433 437
34. J.L. Ritchie, T.M. Bateman, R.O. Bonow, M.H. Crawford, R.J. Gibbons, and R.J. Hall Guidelines for clinical use of cardiac radionuclide imaging. Report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Committee on Radionuclide Imaging), developed in collaboration with the American Society of Nuclear Cardiology J Am Coll Cardiol 25 1995 521 547
35. M.T. Meinardi, W.T. van der Graaf, D.J. van Veldhuisen, J.A. Gietema, E.G. de Vries, and D.T. Sleijfer Detection of anthracycline-induced cardiotoxicity Cancer Treat Rev 25 1999 237 247
36. M. Bountioukos, J.K. Doorduijn, J.R. Roelandt, E.C. Vourvouri, J.J. Bax, and A.F. Schinkel Repetitive dobutamine stress echocardiography for the prediction of anthracycline cardiotoxicity Eur J Echocardiogr 4 2003 300 305
37. Y. Cottin, I. L'huillier, O. Casasnovas, C. Geoffroy, D. Caillot, and M. Zeller Dobutamine stress echocardiography identifies anthracycline cardiotoxicity Eur J Echocardiogr 1 2000 180 183
38. H. Hamada, T. Ohkubo, M. Maeda, and S. Ogawa Evaluation of cardiac reserved function by high-dose dobutamine-stress echocardiography in asymptomatic anthracycline-treated survivors of childhood cancer Pediatr Int 48 2006 313 320
39. M. Jarfelt, V. Kujacic, D. Holmgren, R. Bjarnason, and B. Lannering Exercise echocardiography reveals subclinical cardiac dysfunction in young adult survivors of childhood acute lymphoblastic leukemia Pediatr Blood Cancer 49 2007 835 840
40. M. Maiello, R.K. Sharma, M.M. Ciccone, H.R. Reddy, and P. Palmiero Early diagnosis of cardiac toxicity related to antineoplastic treatment J Cancer Ther 2 2011 161 166
41. J.J. Monsuez, J.C. Charniot, N. Vignat, and J.Y. Artigou Cardiac side-effects of cancer chemotherapy Int J Cardiol 144 2010 3 15
42. S.F. Nagueh, C.P. Appleton, T.C. Gillebert, P.N. Marino, J.K. Oh, and O.A. Smiseth Recommendations for the evaluation of left ventricular diastolic function by echocardiography J Am Soc Echocardiogr 22 2009 107 133
43. J.K. Oh, L. Hatle, A.J. Tajik, and W.C. Little Diastolic heart failure can be diagnosed by comprehensive two-dimensional and Doppler echocardiography J Am Coll Cardiol 47 2006 500 506
44. M.F. Stoddard, J. Seeger, N.E. Liddell, T.J. Hadley, D.M. Sullivan, and J. Kupersmith Prolongation of isovolumetric relaxation time as assessed by Doppler echocardiography predicts doxorubicin-induced systolic dysfunction in humans J Am Coll Cardiol 20 1992 62 69
45. B. Marchandise, E. Schroeder, A. Bosly, C. Doyen, P. Weynants, and R. Kremer Early detection of doxorubicin cardiotoxicity: interest of Doppler echocardiographic analysis of left ventricular filling dynamics Am Heart J 118 1989 92 98
46. S. Tassan-Mangina, D. Codorean, M. Metivier, B. Costa, C. Himberlin, and C. Jouannaud Tissue Doppler imaging and conventional echocardiography after anthracycline treatment in adults: early and late alterations of left ventricular function during a prospective study Eur J Echocardiogr 7 2006 141 146
47. E. Ho, A. Brown, P. Barrett, R.B. Morgan, G. King, and M.J. Kennedy Subclinical anthracycline- and trastuzumab-induced cardiotoxicity in the long-term follow-up of asymptomatic breast cancer survivors: a speckle tracking echocardiographic study Heart 96 2010 701 707
48. N.P. Nikitin, K.K. Witte, S.D. Thackray, R. de Silva, A.L. Clark, and J.G. Cleland Longitudinal ventricular function: normal values of atrioventricular annular and myocardial velocities measured with quantitative two-dimensional color Doppler tissue imaging J Am Soc Echocardiogr 16 2003 906 921
49. R.G. Pai, and K.S. Gill Amplitudes, durations, and timings of apically directed left ventricular myocardial velocities: I. Their normal pattern and coupling to ventricular filling and ejection J Am Soc Echocardiogr 11 1998 105 111
50. J.M. Appel, P. Sogaard, C.E. Mortensen, K. Skagen, and D.L. Nielsen Tissue-Doppler assessment of cardiac left ventricular function during short-term adjuvant epirubicin therapy for breast cancer J Am Soc Echocardiogr 24 2011 200 206
51. V. Mor-Avi, R.M. Lang, L.P. Badano, M. Belohlavek, N.M. Cardim, and G. Derumeaux Current and evolving echocardiographic techniques for the quantitative evaluation of cardiac mechanics: ASE/EAE consensus statement on methodology and indications endorsed by the Japanese Society of Echocardiography J Am Soc Echocardiogr 24 2011 277 313
52. P.W. Stoodley, D.A. Richards, R. Hui, A. Boyd, P.R. Harnett, and S.R. Meikle Two-dimensional myocardial strain imaging detects changes in left ventricular systolic function immediately after anthracycline chemotherapy Eur J Echocardiogr 12 2011 945 952
53. J. Gorcsan III, and H. Tanaka Echocardiographic assessment of myocardial strain J Am Coll Cardiol 58 2011 1401 1413
54. R. Jurcut, H. Wildiers, J. Ganame, J. D'hooge, J. De Backer, and H. Denys Strain rate imaging detects early cardiac effects of pegylated liposomal Doxorubicin as adjuvant therapy in elderly patients with breast cancer J Am Soc Echocardiogr 21 2008 1283 1289
55. J. Ganame, P. Claus, B. Eyskens, A. Uyttebroeck, M. Renard, and J. D'hooge Acute cardiac functional and morphological changes after Anthracycline infusions in children Am J Cardiol 99 2007 974 977
56. J.L. Hare, J.K. Brown, R. Leano, C. Jenkins, N. Woodward, and T.H. Marwick Use of myocardial deformation imaging to detect preclinical myocardial dysfunction before conventional measures in patients undergoing breast cancer treatment with trastuzumab Am Heart J 158 2009 294 301
57. Y.F. Cheung, W.J. Hong, G.C. Chan, S.J. Wong, and S.Y. Ha Left ventricular myocardial deformation and mechanical dyssynchrony in children with normal ventricular shortening fraction after anthracycline therapy Heart 96 2010 1137 1141
58. H. Sawaya, I.A. Sebag, J.C. Plana, J.L. Januzzi, B. Ky, and V. Cohen Early detection and prediction of cardiotoxicity in chemotherapy-treated patients Am J Cardiol 107 2011 1375 1380
59. J.T. Poterucha, S. Kutty, R.K. Lindquist, L. Li, and B.W. Eidem Changes in left ventricular longitudinal strain with anthracycline chemotherapy in adolescents precede subsequent decreased left ventricular ejection fraction J Am Soc Echocardiogr 25 2012 733 740
60. Sawaya H, Sebag IA, Plana JC, Januzzi JL, Ky B, Tan TC, et al. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes and trastuzumab. Circ Cardiovasc Imaging. In press.
61. F. Corapçioglu, N. Sarper, F. Berk, T. Sahin, E. Zengin, and H. Demir Evaluation of anthracycline-induced early left ventricular dysfunction in children with cancer: a comparative study with echocardiography and multigated radionuclide angiography Pediatr Hematol Oncol 23 2006 71 80
62. J. Walker, N. Bhullar, N. Fallah-Rad, M. Lytwyn, M. Golian, and T. Fang Role of three-dimensional echocardiography in breast cancer: comparison with two-dimensional echocardiography, multiple-gated acquisition scans, and cardiac magnetic resonance imaging J Clin Oncol 28 2010 3429 3436
63. S. Takuma, T. Ota, T. Muro, T. Hozumi, R. Sciacca, and M.R. Di Tullio Assessment of left ventricular function by real-time 3-dimensional echocardiography compared with conventional noninvasive methods J Am Soc Echocardiogr 14 2001 275 284
64. R. Wassmuth, S. Lentzsch, U. Erdbruegger, J. Schulz-Menger, B. Doerken, and R. Dietz Subclinical cardiotoxic effects of anthracyclines as assessed by magnetic resonance imaging-a pilot study Am Heart J 141 2001 1007 1013
65. D. Cardinale, M.T. Sandri, A. Colombo, N. Colombo, M. Boeri, and G. Lamantia Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy Circulation 109 2004 2749 2754
66. D. Cardinale, and M.T. Sandri Role of biomarkers in chemotherapy-induced cardiotoxicity Prog Cardiovasc Dis 53 2010 121 129
67. D. Cardinale, A. Colombo, M.T. Sandri, G. Lamantia, N. Colombo, and M. Civelli Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition Circulation 114 2006 2474 2481
68. N. Kalay, E. Basar, I. Ozdogru, O. Er, Y. Cetinkaya, and A. Dogan Protective effects of carvedilol against anthracycline-induced cardiomyopathy J Am Coll Cardiol 48 2006 2258 2262
69. C. Cadeddu, A. Piras, G. Mantovani, M. Deidda, M. Dessì, and C. Madeddu Protective effects of the angiotensin II receptor blocker telmisartan on epirubicin-induced inflammation, oxidative stress, and early ventricular impairment Am Heart J 160 2010 487.e1 487.e7
70. Heart Failure Society of America J. Lindenfeld, N.M. Albert, J.P. Boehmer, S.P. Collins, and J.A. Ezekowitz HFSA 2010 comprehensive heart failure practice guideline J Card Fail 16 2010 e1 e194
71. R.S. Cvetković, and L.J. Scott Dexrazoxane: a review of its use for cardioprotection during anthracycline chemotherapy Drugs 65 2005 1005 1024
72. J.R. Walker, A. Sharma, M. Lytwyn, S. Bohonis, J. Thliveris, and P.K. Singal The cardioprotective role of probucol against anthracycline and trastuzumab-mediated cardiotoxicity J Am Soc Echocardiogr 24 2011 699 705
73. K. Tikoo, M.S. Sane, and C. Gupta Tannic acid ameliorates doxorubicin-induced cardiotoxicity and potentiates its anti-cancer activity: potential role of tannins in cancer chemotherapy Toxicol Appl Pharmacol 251 2011 191 200
74. S. Hamed, I. Barshack, G. Luboshits, D. Wexler, V. Deutsch, and G. Keren Erythropoietin improves myocardial performance in doxorubicin-induced cardiomyopathy Eur Heart J 27 2006 1876 1883
75. M. Agarwal, A. Phan, R. Willix Jr., M. Barber, and E.R. Schwarz Is vitamin D deficiency associated with heart failure? A review of current evidence J Cardiovasc Pharmacol Ther 16 2011 354 363